BioVie Inc. (BIVI)

$1.38

-0.07 (-4.83%)
Rating:
Recommendation:
-
Symbol BIVI
Price $1.38
Beta 2.291
Volume Avg. 0.04M
Market Cap 34.478M
Shares () -
52 Week Range 1.325-17.0
1y Target Est -
DCF Unlevered BIVI DCF ->
DCF Levered BIVI LDCF ->
ROE -1123.60% Strong Sell
ROA -550.30% Strong Sell
Operating Margin -
Debt / Equity 163.07% Buy
P/E -
P/B 3.46 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest BIVI news


Terren Peizer
Healthcare
Biotechnology
NASDAQ Capital Market

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.